Aims/hypothesis Evidence from the USA has emerged that thiazolidinediones may have a negative effect on the skeleton and increase the risk of fracture, but the association between thiazolidinediones use and fractures has not been evaluated in an Asian population. Using the 2000-2005 Taiwan National Health Insurance claims database, this Taiwanese populationbased nested case-control study explored the association between thiazolidinediones use and hospitalisation for bone fracture in type 2 diabetic patients. Methods In the study cohort of type 2 diabetic patients, we identified 18,003 patients with fracture and 90,015 matched controls. Multivariable conditional logistic regressions were used to estimate the association between exposure to thiazolidinediones and fractures. Duration of thiazolidinediones use was defined on the basis of cumulative days of exposure to thiazolidinediones during the year prior to the index date, i.e. <30 days, 30 to 180 days and >180 days. Results More type 2 diabetic patients with fractures than controls used thiazolidinediones (fractures 5.99% vs control 4.06%). Thiazolidinediones use was associated with hospitalisation for fracture and the association was stronger with longer term exposure to thiazolidinediones (<30 Conclusions/interpretation Long-term exposure of type 2 diabetic patients to thiazolidinediones was associated with higher odds of fractures among women without a significant increase in odds of fractures among men.
Introduction
Type 2 diabetes patients have a higher risk of fractures; however, it is unclear whether the increased risk is attributable to patient genetic and demographic factors or treatment of the underlying diseases [1] . Recent evidence has emerged that the widely used thiazolidinediones, oral hypoglycaemic agents known as insulin sensitisers that are often prescribed when other medications have failed to reduce blood glucose levels in patients with type 2 diabetes, may have a negative effect on the skeleton and increase the risk of fracture [2] . Since 2004, preclinical [3] [4] [5] [6] [7] and clinical studies [8] [9] [10] have indicated that thiazolidinediones use could alter bone metabolism, resulting in reduced osteoblastic bone formation and accelerated bone loss. As suggested by recent evidence from an epidemiological study [9] and a clinical trial [11] , thiazolidinediones use is associated with a decrease in bone density in postmenopausal women. Similar findings have been reported in older men with type 2 diabetes [8] . However, most studies to date have addressed the impact of thiazolidinediones use on bone turnover or bone loss in clinical trials. Evidence on how their results link to fracture risk is somewhat limited.
Evidence that thiazolidinediones increase fracture risk emerged with the adverse events reports of the A Diabetes Outcome and Progression Trial (ADOPT) [11, 12] published in 2006. Although a case-control study by Meier et al. [13] provided further evidence of a possible association between thiazolidinediones use and fractures in patients with diabetes mellitus, a dose-response relationship was not confirmed due to the relatively few patients using thiazolidinediones in case and control groups. In addition, the question of whether there is a sex-related difference in the skeletal response to thiazolidinediones was left unanswered. So far, the negative skeletal effects seem to be more significant for women than for men, but results are not conclusive. Findings from ADOPT [12] indicated that the increased risk of fractures occurred only in women. In contrast, an analysis [13] using data derived from the UKbased General Practice Research Database (GPRD) showed that the fracture risk also increased in men. Racial/ethnic differences in fracture risk have been shown in the general population [14] , but no study has evaluated the association between fracture risk and thiazolidinediones use in the Asian population.
Additional studies are warranted as evidence surrounding the fracture risk among thiazolidinediones users stratified by race/ethnicity and sex is limited and studies examining the correlation between length of exposure to thiazolidinediones and fractures are lacking. Specifically, a dose-response relationship between fracture risk and thiazolidinediones use would provide additional evidence and strengthen the proposed relationship. Therefore, using Taiwan's National Health Insurance (NHI) claims database, this large population-based nested case-control study was conducted to explore the dose-response relationship between thiazolidinediones use and risk of fracture in type 2 diabetic patients. Case patient definition and control participants selection In this study population of type 2 diabetic patients, we identified all patients hospitalised with a primary diagnosis of fracture (ICD-9 CM code) between 2001 and 2005. Only the first hospitalisation for fracture was included in our study. Matched controls were chosen at random from the same type 2 diabetic patient cohort. We identified five control participants per case patient. Controls were matched to case patients for age (same year of birth) and sex as well as past medical history, including prior fracture, Paget's disease, osteoporosis, rheumatoid arthritis or osteoarthritis in the prior year, and use of bisphosphates, hormone replacement therapy or corticosteroid in the prior year. We defined an index date for all participants as the date of hospitalisation for fracture for case patients or a random date within the range of the case index dates for controls.
Methods

Data source
Exposure to thiazolidinediones Using NHI database, we assessed whether patients received thiazolidinediones during the year prior to the index date. Thiazolidinediones exposure was inferred from computer-based prescription claims. Duration of thiazolidinediones use was defined according to the number of days thiazolidinediones was taken during the year prior to the index date. In addition, thiazolidinediones users were classified into cohorts according to their cumulative exposure, i.e. <30 days, 30 to 180 days and >180 days.
Statistical analysis Multivariable conditional logistic regression was used to estimate the association between exposure to thiazolidinediones and fractures. Pre-planned secondary analyses were conducted in subgroups stratified by sex or fracture sites. The associations are presented as ORs with 95% CIs. The p values are two-sided, with p< 0.05 considered statistically significant. All models were adjusted for a severity of diabetes proxy (number of hospitalisations for diabetes in the year prior to cohort entry) and co-morbidities potentially associated with an altered fracture risk such as stroke, transient ischaemic attack, asthma or chronic obstructive pulmonary disease (COPD), or drug treatments potentially associated with an altered fracture risk (anticonvulsants, antipsychotic agents, hypnotics/sedatives, diuretics, proton-pump inhibitors and calcium/vitamin D supplements) over 1 year prior to cohort entry. The main analysis included patients with prior fractures and adjusted for these prior fractures, while a sensitivity analysis repeated the analysis excluding patients with prior fractures. All analyses were conducted using SAS software (SAS 9.2; SAS Institute, Cary, NC, USA). 
Results
We identified 18,003 case patients with fracture and 90,015 matched controls. Overall, the age and sex distribution, and prevalence of relevant co-morbidities in case patients and controls were well matched. Compared with controls, case patients had a slightly higher prevalence of stroke and COPD, and higher use of anticonvulsants, antipsychotic agents and hypnotics/sedatives before cohort entry (Table 1) .
More case patients than controls used thiazolidinediones (case 5.99% vs control 4.06%) at any time in the year prior to index date. Thiazolidinediones users differed from nonusers in some aspects of the case and control cohort. As expected, more thiazolidinediones users had been hospital- 
Discussion
In this population-based case-control study, we provide further evidence of an increased association between fractures and use of thiazolidinediones in type 2 diabetic patients. Long-term exposure to thiazolidinediones was associated with higher odds of fracture, with the highest odds seen in thiazolidinediones users with >180 days of use. The dose-response association with exposure was significantly evident in women but not in men.
Our findings are consistent with research done by Meier et al. [13] , which reported increasing ORs of developing a fracture in association with longer thiazolidinediones use. They reported ORs for one to seven, 8-14 and ≥15 thiazolidinediones prescriptions of 0.90 (95% CI 0.46-1.74, p=0.75), 1.85 (95% CI 0.86-3.98, p=0.12) and 2.86 (95% CI 1.57-5.22, p<0.001). Our study uses a more thorough and comprehensive methodological approach by calculating exposure in terms of duration (days) of exposure, an aspect of thiazolidinediones use and fracture risk not discussed in previous studies [12, 14, 16] . Furthermore, by exploring the Taiwanese nationwide data, we had access to a larger diabetes patient cohort than found in existing studies. The large number of fractures cases may provide a more precise estimate with power to look at gradients of relative odds for different durations of exposure to thiazolidinediones. This rich data set enabled us to provide evidence of thiazolidinediones use and odds of fracture that is more relevant to real-world situations.
The use of the Taiwanese NHI dataset provides the first major report of odds of fracture among an Asian population of thiazolidinediones users. Given the common use of thiazolidinediones and relatively lower bone mass in Asian groups [14] , it is important to examine the fracture risk in the potentially vulnerable Asian diabetic population. Our findings not only serve as a comparison to the Western diabetic population, but also suggest clinically relevant warnings surrounding the risk of fracture among Asian thiazolidinediones users. In addition, our study has added evidence on the sex-related difference in skeletal response to thiazolidinediones, with higher odds of fracture in women but not in men. Although a higher odds of fracture risk was found in men receiving ≥180 days of thiazolidinediones, no dose-response relationship was found as in women. Also, the CI in men is very close to 1 (1.02-1.50) and is therefore less clinically relevant. A difference in fracture risk by sex has also been reported in the ADOPT trial [12] et al. [17] . The meta-analysis [17] included ten randomised controlled trials and showed a significantly increased risk of fractures among women (OR 2.23, 95% CI 1.65-3.01, p< 0.001) but not among men (OR 1.00, 95% CI 0.73-1.39). Our findings, therefore, add evidence to support recent warnings [18] issued by the US Food and Drug Administration (FDA) and letters from the manufacturers [19, 20] informing healthcare providers that thiazolidinediones are linked to an increased rate of fractures in women.
Most of the recently published data have indicated that thiazolidinediones-associated fractures are restricted to the upper limb (forearm, hand and wrist) or distal lower limb (foot, ankle, fibula and tibia) [11] . Our study investigated the association between thiazolidinediones use and different fracture sites. Overall, thiazolidinediones use was significantly associated with various kinds of fractures (1.47 Some limitations of the present study should be recognised. First, one of the main inherent limitations of using claim data is the measurement error caused by using the amount of medicine prescribed to define 'exposure', which presumes patients always take the medicines that they have a prescription for. Second, in addition to duration of thiazolidinediones use, dose could be another variable that affects fracture risk. However, over 90% of our thiazolidinediones users received the standard regimen of rosiglitazone 4 mg or pioglitazone 30 mg per day, so there was little variation in dose among the Taiwanese population. Third, the diagnosis of bone fractures was obtained through code diagnoses at hospitalisation. As a result, some events receiving no hospitalisation were excluded. Fourth, the study does not look at long-term thiazolidinediones exposure, which is an area for future research. Fifth, although we adjusted for a wide range of potential fracture risk factors, we were not able to include variables not routinely captured in a claim database, such as certain lifestyle factors (diet or physical activity). Sixth, we did not have a clinical measure of diabetes severity such as HbA 1c , which would be an improvement over the use of the prior diabetic hospitalisation variable used by us. Seventh, we included in our study patients who had a previous history of fracture, rather than excluding them as in an existing study [13] . Although we matched these case patients to controls with a history of fracture, some unobserved fracture risk that could lead to distortion of the fracture risk should be taken into account. We therefore conducted a sensitivity analysis, in which we excluded patients with history of fracture, but results remained unchanged. We thus decided to include patients with previous history of fracture in our study to increase the generalisability of our findings. The final limitation is that, due to the relatively few patients receiving pioglitazone, we were unable to compare fracture odds between rosiglitazone and pioglitazone. Given that current evidence suggests that fracture risk could be a class effect of thiazolidinediones [21] , further studies are needed to examine the fracture risk in rosiglitazone and pioglitazone.
Despite these limitations, our study of a nationwide Asian diabetic population offers additional insight into the use of thiazolidinediones and odds of fractures, especially the sex-specific skeletal effect of thiazolidinediones. Longterm thiazolidinediones use increases the odds of fractures among women without a significant increase in odds of fractures among men in type 2 diabetic patients.
Conclusion
This study is the first to report an association between thiazolidinediones exposure and fracture in an Asian population. Our findings extend the evidence from current literature to a real-world setting and support data from clinical trials suggesting that long-term thiazolidinediones use increases the odds of fractures among women in type 2 diabetic patients. The large sample size also allowed us to confirm an increased odds of fracture across an expanded group of fracture types, extending beyond limbs to include hip and other fractures among thiazolidinediones users.
